More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L

The present post hoc analysis of two 30‐week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan, Puig Domingo, Manuel, Meneghini, Luigi, Napoli, Raffaele, Liu, Minzhi, Soltes Rak, Erika, Aroda, Vanita R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099242/
https://www.ncbi.nlm.nih.gov/pubmed/29785837
http://dx.doi.org/10.1111/dom.13368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099242/
https://www.ncbi.nlm.nih.gov/pubmed/29785837
http://dx.doi.org/10.1111/dom.13368

Ejemplares similares